Sapiens International Co. (NASDAQ:SPNS – Get Free Report) has earned a consensus rating of “Hold” from the five analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $34.25.
Several equities analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $35.00 price target on shares of Sapiens International in a report on Wednesday, February 19th. Barclays increased their price target on Sapiens International from $28.00 to $31.00 and gave the company an “underweight” rating in a report on Friday, May 9th.
Check Out Our Latest Stock Report on Sapiens International
Sapiens International Stock Performance
Sapiens International (NASDAQ:SPNS – Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The technology company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.02. The firm had revenue of $136.11 million for the quarter, compared to analysts’ expectations of $136.25 million. Sapiens International had a return on equity of 17.42% and a net margin of 13.31%. The company’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.36 EPS. Research analysts anticipate that Sapiens International will post 1.42 earnings per share for the current fiscal year.
Sapiens International Increases Dividend
The business also recently announced a semi-annual dividend, which was paid on Wednesday, April 16th. Investors of record on Monday, April 7th were issued a $0.66 dividend. This is a boost from Sapiens International’s previous semi-annual dividend of $0.22. This represents a yield of 2.2%. The ex-dividend date was Monday, April 7th. Sapiens International’s dividend payout ratio (DPR) is currently 46.15%.
Institutional Investors Weigh In On Sapiens International
A number of institutional investors have recently bought and sold shares of the business. Rhumbline Advisers increased its stake in Sapiens International by 467.6% in the 1st quarter. Rhumbline Advisers now owns 264,065 shares of the technology company’s stock worth $7,154,000 after buying an additional 217,540 shares in the last quarter. Jane Street Group LLC increased its stake in Sapiens International by 28.4% in the 1st quarter. Jane Street Group LLC now owns 102,564 shares of the technology company’s stock worth $2,778,000 after buying an additional 22,701 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Sapiens International by 227.2% during the first quarter. Goldman Sachs Group Inc. now owns 550,343 shares of the technology company’s stock valued at $14,909,000 after purchasing an additional 382,138 shares in the last quarter. Millennium Management LLC grew its position in shares of Sapiens International by 217.1% during the first quarter. Millennium Management LLC now owns 371,368 shares of the technology company’s stock valued at $10,060,000 after purchasing an additional 254,259 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of Sapiens International during the first quarter valued at about $209,000. Hedge funds and other institutional investors own 30.73% of the company’s stock.
Sapiens International Company Profile
Sapiens International Corporation N.V. provides software solutions for the insurance industry in North America, the United Kingdom, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides various solutions for property and casualty commercial and personal lines, life and pensions, and reinsurance fields.
Further Reading
- Five stocks we like better than Sapiens International
- Consumer Staples Stocks, Explained
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- How to trade penny stocks: A step-by-step guide
- 3 Stocks Set to Double—And There’s Still Time to Buy
- Growth Stocks: What They Are, Examples and How to Invest
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Sapiens International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sapiens International and related companies with MarketBeat.com's FREE daily email newsletter.